CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

pembrolizumab

Last Updated: December 23, 2020
Result type: Reports
Project Number: PC0235-000
Product Line: Reimbursement Review

Generic Name: pembrolizumab

Brand Name: Keytruda

Manufacturer: Merck Canada Inc.

Therapeutic Area: Colorectal cancer

Indications: ​For the first line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC)

Manufacturer Requested Reimbursement Criteria1: For the first line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC)

Submission Type: Initial

NOC Status at Filing: Pre NOC

Project Status: Active

Companion Diagnostics: Yes

Fee Schedule1: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Submit Feedback

Key Milestones2

Call for patient/clinician input open November 02, 2020
Call for patient/clinician input closed December 24, 2020
Clarification:

- Patient input submission received from Colorectal Cancer Canada and Colorectal Cancer Resource & Action Network

Submission received November 30, 2020
Submission accepted December 14, 2020
Review initiated December 15, 2020
Draft CADTH review report(s) provided to sponsor for comment March 08, 2021
Deadline for sponsors comments March 17, 2021
CADTH responses on draft review report(s) provided to sponsor May 03, 2021
Expert committee meeting (initial) May 14, 2021
Draft recommendation issued to sponsor May 31, 2021
Draft recommendation posted for stakeholder feedback June 10, 2021
End of feedback period June 24, 2021